IFNG and chronic granulomatous disease: An international, prospective, randomized double-blind trial in CGD patients showed clear reduction in severe infections in the IFNγ (50 μg/m2 subcutaneously three times weekly) group without exacerbation of granulomatous or inflammatory complications (22).